Pacira Data Shows EXPAREL Reduces Orthopaedic Care Costs
Event summary
- Pacira BioSciences presented real-world data at the Orthopaedic Research Society 2026 Annual Meeting demonstrating reduced total cost of care for EXPAREL® in total knee arthroplasty (TKA) and spinal fusion procedures.
- Studies, using propensity score matching, showed EXPAREL associated with lower costs compared to ropivacaine and standard of care options.
- The spinal fusion study found reductions primarily driven by a shorter length of hospital stay, with cost savings of approximately $6,000 per patient.
- One TKA study showed cost reductions of $409 in commercial cohorts and $1,359 in Medicare Advantage cohorts.
The big picture
Pacira's data reinforces the trend towards non-opioid pain management solutions, driven by regulatory pressure and patient preference. The demonstrated cost savings of EXPAREL, particularly in inpatient settings, could accelerate adoption by hospitals seeking to reduce expenses and improve patient outcomes. This data provides a tangible economic argument for EXPAREL, potentially expanding its use beyond current indications and increasing its overall market share within the $10 billion orthopaedic pain management market.
What we're watching
- Market Adoption
- The pace at which these cost-savings findings are disseminated and adopted by hospital systems and surgeons will determine EXPAREL’s continued market penetration and revenue growth.
- Competitive Response
- How ropivacaine manufacturers and other pain management solution providers react to this data, and whether they attempt to counter with their own studies or pricing strategies, will shape the competitive landscape.
- Regulatory Scrutiny
- The NOPAIN Act’s potential impact on opioid prescribing and the broader regulatory environment for non-opioid pain management therapies will continue to influence Pacira’s market access and reimbursement rates.
Related topics